Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

p> personnel and the costs the Company's clinical trials and research

initiatives, were $3.5 million in the fourth quarter of 2007, down from

$5.5 million in the previous quarter and $6.3 million in the fourth

quarter of 2006. R&D expenses declined for the full year of 2007 to

$22.0 million, compared to $26.0 million in the prior year. Reduced R&D

expenses resulted mainly from lower spending on the Company's MOXATAG

clinical trial which concluded in 2006.

Selling, general and administrative (SG&A) expenses totaled $5.6

million in the fourth quarter of 2007, down from $6.5 million in the

third quarter of 2007, and $8.3 million in the fourth quarter of 2006.

Fourth quarter SG&A costs declined due to lower third-party costs

associated with the reduced size of Company's contract sales force. For

the full year of 2007, SG&A expenses increased to $26.0 million, from

$21.3 million, as the Company incurred a full year of Keflex 750

selling and marketing expenses in 2007, versus incurring such costs

only during a portion of 2006.

-- Other expenses for the fourth quarter of 2007 included a $2.1 million

noncash expense for the contractual value of warrants issued to

Deerfield Management pursuant to the Keflex transaction in the quarter.

There were no such expenses in prior periods.

-- Net loss for the fourth quarter of 2007 was $9.1 million. This compares

to a net loss of $10.1 million in the third quarter of 2007, and $13.8

million in the fourth quarter of 2006. Net loss for the full year of

2007 was $42.2 million, compared to a net loss of $42.0 million for the

full year of 2006. The net loss for the three months and full year

ended December 31, 2007, was reduced by $0.2 million attributable to

the loss from noncontrolling interest in two compani
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Not long ago, it was ... be performed late in the development cycle – even ... regulatory trends suggest that, like many things GxP, expectations ... recent years, multiple drug sponsors have been required by ... questions during phase I/II. It’s not only clinical trial ...
(Date:8/20/2014)... Sofia, Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the ... rates and connectors for Lucene, SOLR and Elasticsearch. ... change for this high performance triplestore – GraphDB™ ... organizations interested in deploying the only mature enterprise ...
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... Sept. 1 Express Scripts, Inc. (Nasdaq: ESRX ) announced that ... Thomas Weisel Partners Healthcare Conference 2009 on September 9, 2009 at ... , Morgan Stanley Global Healthcare Conference on September 15, 2009 at ... , These presentations will also be broadcast via the Internet ...
... PHILADELPHIA, Sept. 1 ERT (Nasdaq: ERES ), announced ... Keith Schneck, the Company,s Executive Vice President and CFO, are scheduled to ... on September 9, 2009 in New York City, New York. , ... Company,s corporate website at http://www.ert.com . The webcast may ...
... Sept. 1 Environmental Tectonics Corporation,s (OTC Bulletin Board: ETCC) ... sale of a BARA-MED((R)) XD Monoplace Hyperbaric Chamber to ... Georgia area. , , Hyperbaric Oxygen ... the patient breathes 100% oxygen while fully enclosed in a ...
Cached Biology Technology:Express Scripts to Present at Investor Conferences 2ERT to Present at Baird's 2009 Health Care Conference on September 9, 2009 2Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 2Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 3Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 4
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
(Date:8/20/2014)... image of the Para and Mato Grosso states of ... set in order to deforest the land. Deforestation is ... where the land is thereafter converted to a nonforest ... farms, ranches, or urban use. The herringbone-patterned tan lines ... in the middle of the image are evidence of ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... MARC (Maximizing Access to Research Careers) Program has announced ... Summer Research Opportunity Program (SROP). The FASEB MARC Program ... underrepresented groups for summer research experiences in the laboratories ... mentors for the students. The FASEB MARC SROP provides ...
... researchers should welcome the news from the Lawrence Berkeley ... scientists has discovered a new and possibly more effective ... implications for advanced biofuels and therapeutic drugs, as genetically ... to play a key role in the green chemistry ...
... could make more tomatoes taste like heirlooms, reports an international ... scientist. The finding, which will be reported in the ... significant implications for the U.S. tomato industry, which annually harvests ... and fresh-market sales. "This information about the gene responsible ...
Cached Biology News:Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 2Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 3Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 4Programmable DNA scissors found for bacterial immune system 2Programmable DNA scissors found for bacterial immune system 3Discovery may lead to new tomato varieties with vintage flavor and quality 2
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... The FUNNY SHAKERS are multi-functional mixing ... This device is a solid, heavy-duty durable ... is both mixing and vortexing in nature. ... based keypad with digital display to control ...
Biology Products: